Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes
Listen to this summary
The authors aimed to characterize the immunological landscape of different basal cell carcinoma (BCC) subtypes by examining PD-L1, dendritic cells, and HLA expression through immunohistochemistry. Their findings revealed that while PD-L1 was not expressed on BCC tumor cells, it was present on immune cells, particularly in basosquamous BCCs, suggesting that this subtype may be more responsive to anti-PD-1 therapy than others. Overall, the study highlights the immune-privileged status of BCC and challenges existing notions regarding PD-L1 expression in these tumors.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Journal of cutaneous pathology
View all →Jun 9, 2026 · Journal of cutaneous pathology
TFG-Containing Fusions in Melanocytic Tumors: From Polymorphic Read-Through Transcripts to Oncogenic Kinase Fusions
Jun 7, 2026 · Journal of cutaneous pathology
Dermatofibroma Hypocellularity Is Associated With Patient Age: A Retrospective Study of 307 Cases
More in Dermatology
View all →Jun 24, 2026 · The New England journal of medicine
Prevention and Treatment of Peanut Allergy
Jun 24, 2026 · Lancet (London, England)
Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Jun 24, 2026 · The New England journal of medicine
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
Jun 24, 2026 · The New England journal of medicine
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Jun 23, 2026 · Lancet (London, England)
Non-invasive removal of the Smart tracheal occlusion device for fetal congenital diaphragmatic hernia: a single-arm, open-label, phase 1 study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
